The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor

¹Department of Biochemistry and Nutrition, Medical School, Université Libre de Bruxelles, Brussels, Belgium.

|January 1, 1997

Abstract:

RO 25-1553 is a synthetic VIP analogue that induced a long-lasting relaxation of tracheal and bronchial smooth muscles as well as a reduction of edema and eosinophilic mobilization during pulmonary anaphylaxis. In the present study, we tested in vitro the capacity of RO 25-1553 to occupy the different VIP/PACAP receptor subclasses and to stimulate adenylate cyclase activity. The cellular models tested expressed one single receptor subtype: Chinese hamster ovary (CHO) cells transfected with the rat recombinant PACAP I, rat VIP1, and human VIP2 receptors; SUP T1 cells expressing the human VIP2 and HCT 15 and LoVo cells expressing the human VIP1 receptor. RO 25-1553 was threefold more potent than VIP on the human VIP2 receptor, 100- and 600-fold less potent than VIP on the rat and human VIP1 receptors, respectively, and 10-fold less potent than VIP and 3000-fold less potent than PACAP on the PACAP I receptor. RO 25-1553 was a full agonist on the VIP2, the PACAP I, and the rat recombinant VIP1 receptor but a partial agonist only on the human VIP1 receptor. Thus, RO 25-1553 is a highly selective agonist ligand for the VIP2 receptor subclass.

Related Experiment Videos

The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor

Related Concept Videos

Identification of key residues for the binding of glucagon to the N-terminal domain of its receptor: an alanine scan and modeling study.

Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists.

A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.

Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations.

Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.

Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.

In vitro chondrogenic differentiation is improved by the BMP7-derived peptide p[63-82].

Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists.

Erythropoietin-derived peptide (HBSP) inhibits caspase-3/GSDME through HMGB1 to regulate pyroptosis and reduce diabetic retinopathy.

IGF2BP3 drives macrophage M1 polarization to promote intracranial aneurysm rupture through m6A-mediated NPY1R stabilization.

Galanin signaling in stress-induced brain-gut axis dysregulation: Receptor-specific mechanisms and context-dependent pharmacology.

KR-36996, an orally active urotensin II receptor antagonist, attenuates hepatic inflammation and fibrosis in methionine- and choline-deficient diet-induced fibrosing steatohepatitis.

Molecular Characterization of a Novel Mycovirus Isolated from Binucleate Rhizoctonia AG‑Bb strain 8-Q-36.

Two coinfecting archaeal viruses provide insights into virus-virus interactions.

Pulmonary Dirofilaria immitis Infection and Concurrent Pleural Lymphangiomatosis in a Young Woman from Costa Rica: A Diagnostic Challenge after 20 Years of Silence.

On the Application of Respirometric System on Hazelnut Samples to Predict Aflatoxin Production.

Dispersal pathways and infection strategies within the Global Halophilic Virome.

Plscr1 inhibits murine norovirus entry.

Related Experiment Videos

The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor...

Abstract:

Related Concept Videos

Related Articles

The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor